Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?

Tuberkuloz ve Toraks

Volumn 54, Issue 2, 2006, Pages 105-113

  Akkoca Yildiz, Öznur ^a   Önen, Zeynep Pinar ^a   Demir, Gizem ^a   Eriş Gülbay, Banu ^a   Saryal, Sevgi ^a   Karabiyikoǧlu, Gülseren ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

COPD; Exercise capacity; Formoterol; Ipratropium bromide

Indexed keywords

FORMOTEROL; IPRATROPIUM BROMIDE;

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; ERGOMETER; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; LUNG MINUTE VOLUME; MALE; METERED DOSE INHALER; OUTPATIENT; OUTPATIENT DEPARTMENT; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; EXERCISE TEST; FEMALE; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 33747081031     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pauwels RA, Anthonisen N, Bailey WC, et al. GOLD scientific committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: Updated 2003: 55.
2. Belman MJ, Botnic WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-75.
3. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-65.
4. 2-agonist in improving dysnea and exercise limitation in COPD? Chest 1995; 108: 730-5.
5. Liesker JJW, Velde VVD, Meysman M, et al. Effects of formoterol and ipratropium on exercise capacity in patients with COPD. Respir Med 2002; 96: 559-66.
6. Bartow RA, Brogden RN. Formoterol; an update of its pharmacological properties and therapotic efficacy in the management of asthma. Drugs 1998; 55: 303-22.
7. 2-agonist in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60: 307-20.
8. Dahl R, Greefthorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-84.
9. American Thoracic Society. Standardization of spirometry (1994 Update). Am J Respir Crit Care Med 1995; 152: 1107-36.
10. Quanjer P, Tammeling FJ, Cotes JE, et al. Standardised lung function testing; lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6 (Suppl 16): 5-40.
11. American Thoracic Society/American Collage of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-77.
12. Jones NL, Makrides L, Hitchcock C, et al. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 1985; 131: 700-8.
13. Weisman IM, Zeballos RJ. Clinical exercise testing. Clin Chest Med 2001; 22: 679-98.
14. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 1997; 155: 530-5.
15. O'Donnell DE, Bertley JC, Chau LKL, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation. Am J Respir Crit Care Med 1997; 155: 109-15.
16. Aliverti A, Macklem PT. How and why exercise is impaired in COPD. Respiration 2001; 68: 229-39.
17. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. Am Rev Respir Dis 1993; 148: 1351-7.
18. Liesker JJW, Wijkstra PJ, Hacken NHT, et at. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121: 597-608.
19. Tsukino M, Nishimura K, Ikeda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-73.
20. Ikeda A, Nishimura K, Koyama H, et al. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 31: 48-53.
21. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-9.
22. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung functions and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-93.
23. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001; 17: 1132-7.